Kevin Knightly Biography and Net Worth

Insider of IQVIA

Kevin Knightly is President, Corporate Strategy and Enterprise Networks at IQVIA, where he is responsible for evolving the analytics infrastructure and the associated sourcing and production required to support our products and services. In addition, Kevin is also responsible for aligning the company’s corporate strategy and marketing activities to communicate our integrated value proposition to our customers.

Kevin previously served as president, Technology and Commercial Solutions responsible for the growth of the company’s information assets, delivery of innovative offerings for commercial operations, and development of leading-edge database management, patient engagement and end-user technology solutions. With more than two decades of service at IMS Health and its predecessor companies, Kevin has held a variety of senior financial, operations, marketing and general management posts. His roles include serving as senior vice president, Supply Management, senior vice president, Pharma Business Management, and president, Europe, Middle East and Africa. Kevin also was chief financial officer for both IMS Health North America and Europe, and senior vice president, Marketing and Major Markets, EMEA.

Kevin holds a bachelor of science degree in Economics and Accounting from the College of the Holy Cross, and an MBA from New York University’s Stern Business School.

What is Kevin C. Knightly's net worth?: The estimated net worth of Kevin C. Knightly is at least $1.23 million as of February 28th, 2024. Mr. Knightly owns 5,251 shares of IQVIA stock worth more than $1,233,355 as of April 27th. This net worth approximation does not reflect any other assets that Mr. Knightly may own. Additionally, Mr. Knightly receives an annual salary of $1,240,000.00 as Insider at IQVIA. Learn More about Kevin C. Knightly's net worth.
How old is Kevin C. Knightly?: Mr. Knightly is currently 63 years old. There are 3 older executives and no younger executives at IQVIA. Learn More on Kevin C. Knightly's age.
What is Kevin C. Knightly's salary?: As the Insider of IQVIA Holdings Inc., Mr. Knightly earns $1,240,000.00 per year. There are 3 executives that earn more than Mr. Knightly. The highest earning executive at IQVIA is Mr. Ari Bousbib, CEO & Chairman, who commands a salary of $7,150,000.00 per year. Learn More on Kevin C. Knightly's salary.
How do I contact Kevin C. Knightly?: The corporate mailing address for Mr. Knightly and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on Kevin C. Knightly's contact information.
Has Kevin C. Knightly been buying or selling shares of IQVIA?: Kevin C. Knightly has not been actively trading shares of IQVIA during the last quarter. Most recently, Kevin C. Knightly sold 8,607 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a transaction totalling $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares of the company's stock, valued at $1,313,642.67. Learn More on Kevin C. Knightly's trading history.
Who are IQVIA's active insiders?: IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), and Eric Sherbet (Insider). Learn More on IQVIA's active insiders.
Are insiders buying or selling shares of IQVIA?: In the last year, insiders at the medical research company sold shares 7 times. They sold a total of 87,540 shares worth more than $20,013,870.89. The most recent insider tranaction occured on March, 1st when insider Ari Bousbib sold 31,678 shares worth more than $7,936,289.34. Insiders at IQVIA own 1.6% of the company. Learn More about insider trades at IQVIA.
Information on this page was last updated on 3/1/2024.

Kevin C. Knightly Insider Trading History at IQVIA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/28/2024	Sell	8,607	$250.17	$2,153,213.19	5,251
12/1/2023	Sell	13,117	$214.03	$2,807,431.51	7,347
6/5/2023	Sell	5,820	$201.89	$1,174,999.80	1,973
5/26/2023	Sell	1	$198.66	$198.66	1,973
2/16/2023	Sell	4,446	$225.61	$1,003,062.06	1,973
8/1/2019	Sell	4,278	$158.50	$678,063.00	4,084
7/29/2019	Sell	6,945	$158.53	$1,100,990.85
5/3/2019	Sell	46,080	$138.06	$6,361,804.80
9/7/2018	Sell	9,216	$126.46	$1,165,455.36
8/25/2017	Sell	19,339	$99.51	$1,924,423.89	40,650
8/9/2017	Sell	20,000	$90.28	$1,805,600.00	46,826

Kevin C. Knightly Buying and Selling Activity at IQVIA

IQVIA Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Today's Range

Now: $234.88

$233.10

$236.93

50 Day Range

MA: $245.28

$227.17

$259.15

2 Week Range

Now: $234.88

$167.42

$261.73

Volume

635,995 shs

Average Volume

970,046 shs

Market Capitalization

$42.63 billion

P/E Ratio

32.22

Dividend Yield

N/A

Beta

1.5

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Kevin Knightly Biography and Net Worth

What is Kevin C. Knightly's net worth?

How old is Kevin C. Knightly?

What is Kevin C. Knightly's salary?

How do I contact Kevin C. Knightly?

Has Kevin C. Knightly been buying or selling shares of IQVIA?

Who are IQVIA's active insiders?

Are insiders buying or selling shares of IQVIA?